Delta-8 THC Shows Promise Against Autoimmune Liver Injury

A new mouse study suggests delta-8 THC may protect the liver by restoring immune balance and changing how key genes are regulated. The findings reveal a promising biological pathway, but they do not establish delta-8 as a treatment for people with autoimmune hepatitis.

Delta-8 THC is usually discussed as a milder intoxicating relative of delta-9 THC or as a controversial product of the hemp market. New research, however, places the minor cannabinoid in a very different context: the regulation of immune cells during autoimmune liver injury.

A 2026 study published in International Immunopharmacology¹ found that delta-8 tetrahydrocannabinol reduced liver damage and inflammation in female mice with experimentally induced autoimmune hepatitis. More significantly, the researchers identified an epigenetic pathway that may help explain the effect. Delta-8 THC restored two microRNAs that suppress mTOR, a major regulator of immune-cell growth and specialization.

The result is not evidence that retail delta-8 products can treat liver disease. It is evidence that a relatively understudied cannabinoid may influence the immune system with greater precision than the broad phrase “anti-inflammatory” suggests.

What Is Autoimmune Hepatitis?

Autoimmune hepatitis is a chronic condition in which the immune system attacks healthy liver tissue. Continued inflammation can cause fibrosis, cirrhosis, liver failure, and, in severe cases, the need for transplantation. The disease is associated with a breakdown in immune tolerance, the body’s ability to distinguish genuine threats from its own cells.

Treatment commonly relies on corticosteroids and other immunosuppressive medications. The standard autoimmune hepatitis treatments can be highly effective, but long-term immune suppression may produce adverse effects, and some patients relapse or respond incompletely. That creates a rationale for studying compounds that can rebalance particular immune pathways instead of simply suppressing immune activity across the body.

The researchers tested delta-8 THC in a widely used mouse model created with concanavalin A, or ConA. This compound rapidly activates immune cells and causes acute liver inflammation resembling some immunological features of human autoimmune hepatitis. It is useful for examining mechanisms, but it does not reproduce the full complexity or chronic progression of the human disease.

Delta-8 THC Reduced Multiple Signs of Liver Injury

Female mice received delta-8 THC before the ConA challenge and again 30 minutes afterward. A dose-finding experiment compared 10, 20, and 40 milligrams per kilogram, with 20 milligrams per kilogram producing the strongest overall protection without what the researchers considered excessive immunosuppression. At that dose, the observed immunomodulatory effects were comparable to those produced by methylprednisolone in the preliminary comparison.

Untreated ConA-exposed mice developed extensive liver injury, including necrosis, immune-cell infiltration, enlarged sinusoidal spaces, and disruption of normal liver architecture. Delta-8 THC substantially reduced each of these features. It also lowered the ConA-driven elevations in ALT and AST, enzymes released into the blood when liver cells are damaged.

The protection was not limited to liver tissue. Delta-8 THC reduced inflammatory cytokines and changed the mixture of immune cells entering or remaining within the liver. These findings complement broader research showing that CBD and THC may alter immune-cell development, although the cannabinoids, experimental systems, and health implications differ.

Delta-8 THC Appeared to Rebalance the Immune Response

Inflammation depends not only on how many immune cells are present, but also on which populations dominate and what instructions they receive. ConA increased inflammatory monocytes, neutrophils, natural killer cells, and inflammatory CD4+ T cells. Delta-8 THC suppressed several of these populations while preserving Kupffer cells, the resident macrophages that help maintain normal liver function and immune tolerance.

The cannabinoid also shifted CD4+ T-cell differentiation. It reduced Th1 and Th17 cells, which can drive inflammatory damage, while increasing regulatory T cells, commonly called Tregs. These regulatory cells restrain excessive immune responses and help prevent the immune system from attacking healthy tissue.

This distinction matters. A compound that indiscriminately shuts down immune function could leave the body more vulnerable to infections and other threats. The study instead describes a redistribution toward a more tolerogenic immune environment. Further research must determine whether that pattern is reproducible, durable, and safe.

The reported immune changes included:

• Fewer inflammatory monocytes and neutrophils in the liver
• Reduced Th1, Th17, and natural killer cell activity
• Preservation of tolerogenic Kupffer cells
• Expansion of regulatory T cells

An Epigenetic Pathway May Explain the Effect

The most novel part of the research concerns microRNAs, small molecules that regulate gene expression after DNA has been transcribed. They do not rewrite the underlying genetic code. Instead, they influence which genetic instructions are translated into proteins and how strongly those instructions are expressed.

Researchers identified 106 microRNAs whose expression differed among the experimental groups. Two stood out: miR-100-5p and miR-199a-3p. Both were abundant in healthy liver tissue, sharply reduced after ConA exposure, and restored following delta-8 THC treatment.

Both microRNAs target mTOR, a central signaling protein that integrates information about nutrients, growth factors, cellular stress, and immune activation. The mTOR signaling pathway helps determine whether T cells develop into inflammatory or regulatory populations. Excessive or poorly controlled mTOR activity is implicated in numerous immune, metabolic, and proliferative disorders.

Delta-8 THC reduced mTOR expression and lowered activation of a downstream protein called p70 S6 kinase. The researchers then used microRNA mimics and inhibitors in cultured mouse cells. Increasing miR-100-5p or miR-199a-3p suppressed mTOR, while inhibiting the microRNAs increased it. Manipulating the same microRNAs also shifted T-cell development away from inflammatory phenotypes and toward regulatory cells.

This gives the paper a mechanistic chain rather than a simple association: delta-8 THC was linked to restored microRNAs, lower mTOR signaling, altered T-cell differentiation, and reduced liver inflammation. Nevertheless, the researchers did not complete every experiment needed to prove that this chain directly caused the protection observed in living mice.

Why This Finding Is Bigger Than Delta-8 THC

The commercial identity of delta-8 can obscure the scientific significance of the study. Much of the retail market consists of intoxicating products manufactured by chemically converting hemp-derived CBD because cannabis naturally contains only small amounts of delta-8 THC. Product purity, dose accuracy, residual chemicals, and legal status vary widely.

The researchers used delta-8 THC with a reported HPLC purity of 99.6 percent under controlled laboratory conditions. That is fundamentally different from purchasing an unverified vape or gummy. Readers should not interpret the findings as validation of commercial products or as support for self-treating autoimmune hepatitis.

Instead, the study strengthens a broader idea: cannabinoids may be useful as molecular probes for discovering drug targets. Delta-8 THC’s value may ultimately come from revealing how cannabinoid receptors, microRNAs, and mTOR interact, even if a future medicine uses a refined derivative or targets the same pathway without causing intoxication.

This is also why the persistent barriers described in cannabinoid research matter. Without standardized compounds, rigorous dose studies, and clinically relevant models, promising laboratory signals remain difficult to translate into safe medicines.

What the Study Does Not Prove

The limitations are substantial. Only female mice were studied. Delta-8 THC was administered before liver injury, so the experiment primarily demonstrates prevention rather than treatment of established disease. The ConA model produces rapid, acute inflammation, whereas autoimmune hepatitis in people is chronic and biologically more complicated.

The study also did not determine whether CB1 receptors, CB2 receptors, or both mediated the protection. That question is especially relevant because weaker CB1 activity is often used to explain delta-8 THC’s lower psychoactive potency, while CB2 is closely associated with immune regulation. Recent research on THC activation of cannabinoid receptors further illustrates that receptor behavior can vary with the compound and biological context.

Future studies will need to test delta-8 THC after disease has begun, examine chronic models, include both sexes, establish receptor involvement, evaluate long-term safety, and eventually assess whether the mechanism appears in human cells and patients.

A Promising Mechanism, Not a New Liver Treatment

The study provides unusually detailed evidence for an early-stage cannabinoid experiment. Delta-8 THC did not merely lower a single inflammatory marker. It protected liver structure, changed multiple immune populations, restored two regulatory microRNAs, suppressed mTOR signaling, and favored the development of regulatory T cells.

That combination makes the research worthy of attention, but not clinical conclusions. For now, the most defensible takeaway is that delta-8 THC has exposed a potentially valuable immune-regulation pathway. Whether scientists can turn that pathway into a safe therapy for autoimmune hepatitis or other inflammatory disorders remains an open question.

References:

¹ Hamida, H., Kakar, K., Palrasu, M., Marudamuthu, A., Yang, X., Halder, U., Wilson, K., Nagarkatti, P., & Nagarkatti, M. (2026). Delta-8-tetrahydrocannabinol ameliorates murine autoimmune hepatitis and is associated with epigenetic modulation of immune responses. International Immunopharmacology, 189, 117404. https://doi.org/10.1016/j.intimp.2026.117404